Formulation Development

MARKET BRIEF – Miniaturizing Healthcare – From Microelectronics to Nanobiosensing

Cecilia Van Cauwenberghe, MS, Technical Insights Senior Research Analyst, Frost & Sullivan, reports that the proliferation of lower cost microfluidics-based genomics tools offering improved capabilities and allowing more access to end-users is expected to drive this technology for pharmaceutical and biomedical research throughout the next 5 years.

EXECUTIVE INTERVIEW – Ascendia Pharmaceuticals: Sophisticated Formulations for Poorly Soluble Drugs

Jingjun (Jim) Huang, PhD, CEO, and Founder of Ascendia, discusses his company’s unique vision and strategy to provide pharmaceutical companies with a contract research partner that can provide technologies in order to efficiently determine which approach is most suitable for a given molecule.

STANDARDIZATION TECHNOLOGY – Innovative Temperature Standardization Technology Supports Cell Therapy Clinical Trials

Rolf O. Ehrhardt, MD, PhD, and Maria Thompson, PhD, discuss a unique proprietary temperature standardization technology that is practical for all stages of cell processing and handling. It is currently supporting a Phase IIb clinical trial investigating the efficacy of an immunotherapy treatment for patients with moderate-to-severe refractory Crohn’s disease.

EXCLUSIVE ONLINE CONTENT

12/17/2018

Croda Acquires Biosector; Strengthens Pharmaceutical Offering

Croda International Plc, the speciality chemical company that creates high performance ingredients and technologies relied upon by industry and consumers globally, recently announced that it has strengthened its pharmaceutical offering by signing a definitive agreement with Brenntag Nordic A/S to acquire Brenntag Biosector (Biosector).

12/11/2018

Quotient Sciences & Druggability Technologies Announce Collaboration

Quotient Sciences and Druggability Technologies recently announced a collaboration to utilize Quotient’s integrated Translational Pharmaceutics platform to advance the development of DRGT-46, a novel, fast-acting formulation of celecoxib using proprietary super-API compositions developed by DRGT.

12/11/2018

Cambrex Expands Analytical Capabilities

Cambrex Corporation recently announced it is investing $1 million at its High Point, NC, site to fit out 1,300 sq ft of analytical laboratory space and plans to hire 9 chemical research and development scientists, as well as 6 analytical research and development scientists pursuant to this project.